740 results on '"Stone, Nelson N."'
Search Results
152. THE INCIDENCE AND CHARACTERIZATION OF THE METABOLIC SYNDROME IN A PROSTATE CANCER SCREENING POPULATION
153. PREDICTORS OF THE ANDROGEN DEFICIENCY IN MEN (ADAM) SYNDROME IN A PROSTATE CANCER SCREENING POPULATION
154. Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy
155. Effect of Family History on Outcomes in Patients Treated With Definitive Brachytherapy for Clinically Localized Prostate Cancer
156. Association of Single Nucleotide Polymorphisms inSOD2, XRCC1andXRCC3with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer
157. In Reply to Drs. Oton and Oton
158. Do high radiation doses in locally advanced prostate cancer patients treated with Pd-103 implant plus external beam irradiation cause increased urinary, rectal and sexual morbidity?
159. Treatment of T3B prostate cancer with a combination of hormonal therapy, permanent brachytherapy and external beam irradiation
160. TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy
161. 125I Monotherapy Using D90 Implant Doses of 180 Gy or Greater
162. Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes
163. Brachytherapy for the Treatment of Prostate Cancer
164. A Genetically Determined Dose–Volume Histogram Predicts for Rectal Bleeding among Patients Treated With Prostate Brachytherapy
165. 1763: Multicenter Analysis of Outcomes in Patients Treated with Permanent Prostate Brachytherapy: Effect of PSA Failure Definition and Dose on Biochemical Defined Relapse
166. 178
167. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease
168. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control
169. 1361: A Modified American Urological Association (AUA) Symptom Score
170. 1324: Diurnal Serum Testosterone Variation in Aging Men: Cross-Sectional Analysis from a Large National Screening Program Reveals Only a Modest Decline Beginning in the Mid-Afternoon
171. 535: Relationships of Life Style with PSA, Testosterone and Cholesterol in a Large Cohort of Men Screened or Prostate Cancer
172. 671: Long-Term Patterns of Local Failure Following Prostate Brachytherapy
173. 1342: Urinary, Sexual and Rectal Morbidity in Patients Treated with 1-125 Prostate Brachytherapy Followed at Least 5 Years
174. 669: Long-Term Disease Free Survival Following Prostate Brachytherapy
175. Disease-specific survival following the brachytherapy management of prostate cancer
176. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results
177. 1075: ATM Sequence Variants are Predictive of the Development of Erectile Dysfunction Among Patients Treated for Prostate Cancer with 125Iodine Brachytherapy
178. 1032: The Effect of Brachytherapy on Prostate Gland Size
179. 1009: I-125 Brachytherapy and Localized Prostate Cancer: Outcome Results with 5-Year Minimum Follow-Up
180. INTERMEDIATE TERM BIOCHEMICAL-FREE PROGRESSION AND LOCAL CONTROL FOLLOWING 125 IODINE BRACHYTHERAPY FOR PROSTATE CANCER
181. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer
182. Does prior transurethral resection of prostate compromise brachytherapy quality: A dosimetric analysis
183. Serum Interleukin-8 is Elevated in Men with Prostate Cancer and Bone Metastases
184. Combined modality treatment in the management of high-risk prostate cancer
185. 828: Long-Term Morbidity in Patients Treated with I-125 Prostate Brachytherapy Followed a Minimum of 4 Years
186. Influence of prostate volume on dosimetry results in real-time 125I seed implantation
187. Urinary symptom flare following I-125 prostate brachytherapy
188. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications
189. Permanent seed implantation for localized adenocarcinoma of the prostate
190. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation
191. Increased serum insulin associated with increased risk of prostate cancer recurrence
192. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society
193. Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome
194. Biopsy Results after Real-Time Ultrasound-Guided Transperineal Implants for Stage T1-T2 Prostate Cancer
195. Prostate brachytherapy in patients with prostate volumes ≥ 50 cm3: dosimetic analysis of implant quality
196. 15-Year Cause Specific and All-Cause Survival Following Brachytherapy for Prostate Cancer: Negative Impact of Long-Term Hormonal Therapy.
197. Does prostate brachytherapy treat the seminal vesicles? A dose–volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation
198. PROSTATE BRACHYTHERAPY
199. RELATIONSHIP OF GLEASON SCORE (GS), PROSTATE SPECIFIC ANITGEN (PSA), CLINICAL STAGE (CS), AND SEMINAL VESICLE INVOLVEMENT (SVI) TO PELVIC LYMPH NODE (PLN) METASTASES AS DETERMINED BY REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) FOR PSA AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) IN MEN WITH PROSTATE CANCER
200. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.